Your browser doesn't support javascript.
Use of the Monoclonal Antibody Regdanvimab to Treat Patients Hospitalized with COVID-19: Real-World Data during the Delta Variant Predominance.
Kwak, Yee Gyung; Song, Je Eun; Kang, Jieun; Kang, Jiyeon; Kang, Hyung Koo; Koo, Hyeon-Kyoung; Park, Hye Kyeong; Choi, Sang Bong; Lee, Hyuk Pyo; Lee, Myung Jin; Kim, Baek-Nam.
  • Kwak YG; Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea.
  • Song JE; Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea.
  • Kang J; Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea.
  • Kang J; Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea.
  • Kang HK; Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea.
  • Koo HK; Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea.
  • Park HK; Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea.
  • Choi SB; Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul, Korea.
  • Lee HP; Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul, Korea.
  • Lee MJ; Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul, Korea.
  • Kim BN; Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul, Korea. kimbn@paik.ac.kr.
Infect Chemother ; 2022 Sep 07.
Article in English | MEDLINE | ID: covidwho-2066723
ABSTRACT
Regdanvimab is the only monoclonal antibody available in Korea that targets severe acute respiratory syndrome coronavirus 2. We retrospectively evaluated the clinical characteristics of 374 adults hospitalized with coronavirus disease 2019 (COVID-19) who were treated with regdanvimab from September through December 2021. In total, 322 (86.1%) patients exhibited risk factors for disease progression. Most patients (91.4%) improved without additional treatment. No patient died or was transferred to intensive care. This study shows that regdanvimab prevented disease progression in high-risk patients with mild to moderate COVID-19 infections during Delta variant predominance.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Topics: Variants Language: English Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Topics: Variants Language: English Year: 2022 Document Type: Article